Fig. 2From: Bioinformatics analysis reveals the potential target of rosiglitazone as an antiangiogenic agent for breast cancer therapyA Interaction between RGZ and its direct target proteins (DTPs), as analyzed using STITCH. B Venn Diagram analysis between RGZ targets and breast cancer (BC) angiogenesis regulatory genes, resulting in potential target of RGZ against angiogenesis (TR)Back to article page